Shunt Infections

Status: draft · Last updated 2026-10-23 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Incidence: about 12% per patient over 24 months nationally . About 4–5% per procedure in modern quality networks .
  • Strongest risk factor: revision surgery (HR 3.9 for one revision, 13.0 for two or more) .
  • Other major risk factors: postoperative CSF leak (HR 19), prematurity, glove breaches . Also gastrostomy and shunt surgery within the previous 12 weeks .
  • Organisms: coagulase-negative staphylococci > S. aureus > gram-negative bacilli > P. acnes. Gram-negatives are more common after antibiotic-impregnated catheters .
  • Treatment: remove the shunt, place an EVD, give vancomycin plus an antipseudomonal beta-lactam, and reimplant when the CSF is sterile .
  • IDSA durations: 10–14 days for most organisms, 21 days considered for gram-negatives .
  • Externalization vs full removal: no high-level evidence favors complete removal over externalization . Longer antibiotic courses do not reduce reinfection .
  • Prophylaxis: systemic antibiotic prophylaxis works (OR 0.51), and doses beyond 24 hours add no proven benefit .
  • Antibiotic-impregnated catheters: cut infection from 6% to 2% in BASICS, now a Level I recommendation. Silver catheters don't help .
  • Protocols: checklist-based protocols lower infection, and compliance matters (5.0% vs 8.7%) .

Landmark papers

  • BASICS (Mallucci et al., Lancet 2019): a randomized trial of 1,605 patients of all ages at 21 UK and Irish centers. Revision for infection occurred in 2% with antibiotic-impregnated shunts vs 6% with standard shunts (cause-specific HR 0.38), and silver-impregnated shunts gave no benefit .
  • HCRN protocol (Kestle et al., J Neurosurg Pediatr 2011): HCRN's first standardized protocol lowered the infection rate from 8.8% to 5.7%, a 36% relative reduction .
  • IDSA ventriculitis and meningitis guideline (Tunkel et al., Clin Infect Dis 2017): recommends complete removal of the infected shunt, an EVD and IV antibiotics (strong recommendation, moderate-quality evidence) .

Incidence, etiology, risk factors and organisms

Infection is one of the most consequential complications of CSF shunting. Across 41 US children's hospitals, 11.7% of 7,071 children developed a shunt infection within 24 months of an uncomplicated first shunt placement. That is 7.2% per procedure, and hospital rates ranged from 4.1% to 20.5% per patient . Rates in the Hydrocephalus Clinical Research Network's quality-improvement work (HCRN, a multicenter North American research group) are lower, about 5% per procedure and 3.6% across 31 sites . Most infections come from skin flora that contaminate the hardware at surgery. In a prospective cohort in which a research nurse observed each operation, three factors predicted infection: a postoperative CSF leak (HR 19.2), prematurity (HR 4.7) and each exposure of the shunt to a breached surgical glove (HR 1.07 per exposure) . Revision surgery is the strongest risk factor. Compared with no revision, one revision raised the risk of first infection about fourfold (HR 3.9) and two or more raised it thirteenfold (HR 13.0). Having a gastrostomy tube doubled it (HR 2.0) . Other risk factors include:

Among 145 culture-positive first infections in HCRN children, the organisms were coagulase-negative staphylococci (36%), Staphylococcus aureus (32%), gram-negative bacilli (26%) and Propionibacterium (Cutibacterium) acnes (6%). Gram-negative bacilli caused a larger share of infections (52%) when antibiotic-impregnated catheters had been used at the first shunt placement .

Evidence-based treatment

Treatment combines surgery with antibiotics. A decision analysis found the best expected outcome with shunt removal, external ventricular drainage (EVD) or ventricular taps, antibiotics, and a new shunt once the CSF is sterile. That approach scored 0.86, compared with 0.76 for removal with immediate replacement and 0.61 for antibiotics alone . The 2017 Infectious Diseases Society of America (IDSA) guideline gives these recommendations :

The CNS/AANS pediatric hydrocephalus guideline supports removing hardware, either fully or by externalizing the distal catheter, alongside antibiotics (Level II). The evidence is insufficient to favor complete removal over externalization, or to support routine intrathecal antibiotics (Level III) . In an HCRN cohort of 233 children with a first infection, 75% were treated with total shunt removal and an EVD, and 16% developed reinfection over a median of 44 days. Neither the surgical approach nor the length of IV antibiotics was independently linked to reinfection. Approaches other than total removal trended toward more reinfection, and rifampin use toward less, but neither reached statistical significance . HCRN surgeons usually gave IV antibiotics for longer than the IDSA recommends, and the longer courses did not lower reinfection rates (12% reinfection with longer-than-recommended treatment) .

Evidence-based prevention

Systemic antibiotic prophylaxis reduces infection. A systematic review of 17 trials (2,134 patients) found an odds ratio of 0.51, with no clear benefit from continuing antibiotics beyond the first 24 hours . The pediatric guideline meta-analysis found 5.9% infection with prophylaxis vs 10.7% without (RR 0.55; Level II) . Antibiotic-impregnated catheters (clindamycin and rifampicin) have the strongest evidence. In the BASICS randomized trial (1,605 patients of all ages, 21 UK and Irish centers), revision for infection occurred in 2% with antibiotic-impregnated shunts vs 6% with standard shunts (cause-specific HR 0.38). Silver-impregnated shunts gave no benefit (6%) . Accordingly, the 2020 CNS/AANS guideline update upgraded its recommendation for antibiotic-impregnated tubing from Level III to Level I . Standardized surgical protocols also help. HCRN's first protocol lowered the infection rate from 8.8% to 5.7%, a 36% relative reduction. Using antiseptic cream instead of a formal surgical scrub was linked to higher risk (OR 4.53) . Under the second protocol, infection rates were 5.0% when every step was followed vs 8.7% when it wasn't . In the third HCRN protocol (4,913 procedures), infection fell from 8.1% with the protocol alone to 4.9% when antibiotic-impregnated catheters were added. Both these catheters (OR 0.70) and vancomycin wound irrigation (OR 0.36) were independently protective, but the role of vancomycin irrigation needs further study . Not every study agrees. In a six-hospital observational cohort of lower-risk initial shunt placements and revisions, neither intrathecal antibiotics nor antibiotic-impregnated catheters significantly reduced infection compared with standard care . Across 31 HCRN quality sites, adopting a protocol was not linked to infection risk, and antibiotic ointment was linked to higher risk . Technique remains central: prevent CSF leaks, minimize handling of the hardware and consider double gloving .

Related topics

References

  1. Simon TD, Hall M, Riva-Cambrin J, et al. Infection rates following initial cerebrospinal fluid shunt placement across pediatric hospitals in the United States. J Neurosurg Pediatr 2009;4(2):156–165. doi:10.3171/2009.3.PEDS08215. PMID 19645551. verified
  2. Kulkarni AV, Drake JM, Lamberti-Pasculli M. Cerebrospinal fluid shunt infection: a prospective study of risk factors. J Neurosurg 2001;94(2):195–201. doi:10.3171/jns.2001.94.2.0195. PMID 11213954. verified
  3. Simon TD, Butler J, Whitlock KB, et al. Risk factors for first cerebrospinal fluid shunt infection: findings from a multi-center prospective cohort study. J Pediatr 2014;164(6):1462–1468.e2. doi:10.1016/j.jpeds.2014.02.013. PMID 24661340. verified
  4. Chu J, Jensen H, Holubkov R, et al. The Hydrocephalus Clinical Research Network quality improvement initiative: the role of antibiotic-impregnated catheters and vancomycin wound irrigation. J Neurosurg Pediatr 2022;29(6):711–718. doi:10.3171/2022.2.PEDS2214. PMID 35303708. verified
  5. Tamber MS, Jensen H, Reeder R, et al. Effect of a recommended shunt infection prevention protocol on perioperative practices and infection rates in the Hydrocephalus Clinical Research Network-Quality. J Neurosurg Pediatr 2025;36(6):677–682. doi:10.3171/2025.7.PEDS25208. PMID 41105981. verified
  6. Simon TD, Kronman MP, Whitlock KB, et al. Patient and treatment characteristics by infecting organism in cerebrospinal fluid shunt infection. J Pediatric Infect Dis Soc 2019;8(3):235–243. doi:10.1093/jpids/piy035. PMID 29771360. verified
  7. Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. Clin Infect Dis 2017;64(6):e34–e65. doi:10.1093/cid/ciw861. PMID 28203777. Full text (PMC) verified
  8. Schreffler RT, Schreffler AJ, Wittler RR. Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J 2002;21(7):632–636. doi:10.1097/00006454-200207000-00006. PMID 12237594. verified
  9. Tamber MS, Klimo P Jr, Mazzola CA, et al. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 8: Management of cerebrospinal fluid shunt infection. J Neurosurg Pediatr 2014;14 Suppl 1:60–71. doi:10.3171/2014.7.PEDS14328. PMID 25988784. verified
  10. Simon TD, Kronman MP, Whitlock KB, et al. Reinfection after treatment of first cerebrospinal fluid shunt infection: a prospective observational cohort study. J Neurosurg Pediatr 2018;21(4):346–358. doi:10.3171/2017.9.PEDS17112. PMID 29393813. verified
  11. Simon TD, Kronman MP, Whitlock KB, et al. Reinfection rates following adherence to Infectious Diseases Society of America guideline recommendations in first cerebrospinal fluid shunt infection treatment. J Neurosurg Pediatr 2019;23(5):577–585. doi:10.3171/2018.11.PEDS18373. PMID 30771757. verified
  12. Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts: a systematic review. J Neurosurg Pediatr 2008;1(1):48–56. doi:10.3171/PED-08/01/048. PMID 18352803. verified
  13. Klimo P Jr, Van Poppel M, Thompson CJ, et al. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 6: Preoperative antibiotics for shunt surgery in children with hydrocephalus: a systematic review and meta-analysis. J Neurosurg Pediatr 2014;14 Suppl 1:44–52. doi:10.3171/2014.7.PEDS14326. PMID 25988782. verified
  14. Mallucci CL, Jenkinson MD, Conroy EJ, et al. Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation. Lancet 2019;394(10208):1530–1539. doi:10.1016/S0140-6736(19)31603-431603-4). PMID 31522843. verified
  15. Klimo P Jr, Thompson CJ, Baird LC, et al. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 7: Antibiotic-impregnated shunt systems versus conventional shunts in children: a systematic review and meta-analysis. J Neurosurg Pediatr 2014;14 Suppl 1:53–59. doi:10.3171/2014.7.PEDS14327. PMID 25988783. verified
  16. Bauer DF, Baird LC, Klimo P, et al. Congress of Neurological Surgeons systematic review and evidence-based guidelines on the treatment of pediatric hydrocephalus: update of the 2014 guidelines. Neurosurgery 2020;87(6):1071–1075. doi:10.1093/neuros/nyaa434. PMID 34791462. verified
  17. Kestle JR, Riva-Cambrin J, Wellons JC 3rd, et al. A standardized protocol to reduce cerebrospinal fluid shunt infection: the Hydrocephalus Clinical Research Network Quality Improvement Initiative. J Neurosurg Pediatr 2011;8(1):22–29. doi:10.3171/2011.4.PEDS10551. PMID 21721884. verified
  18. Kestle JR, Holubkov R, Douglas Cochrane D, et al. A new Hydrocephalus Clinical Research Network protocol to reduce cerebrospinal fluid shunt infection. J Neurosurg Pediatr 2016;17(4):391–396. doi:10.3171/2015.8.PEDS15253. PMID 26684763. verified
  19. Podkovik S, Zhou C, Coffin SE, et al. Antibiotic impregnated catheters and intrathecal antibiotics for CSF shunt infection prevention in children undergoing low-risk CSF shunt surgery. BMC Pediatr 2024;24(1):325. doi:10.1186/s12887-024-04798-9. PMID 38734598. verified

Verification (2026-10-23): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Every figure cited was checked against the PubMed abstract, and the IDSA recommendations against the guideline's full text on PMC. Other full texts were not reviewed.